NERV - Minerva Neurosciences, Inc.
| Previous Close | 6.77 |
| Open | 6.86 |
| Bid | 7.14 x 2900 |
| Ask | 7.15 x 1800 |
| Day's Range | 6.62 - 7.27 |
| 52 Week Range | 4.01 - 8.83 |
| Volume | 390,377 |
| Avg. Volume | 378,570 |
| Market Cap | 280.203M |
| Beta (3Y Monthly) | 1.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.42 |
| Earnings Date | Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.20 |
- GlobeNewswire
SI-BONE Names Jeryl (“Jeri”) Hilleman to Board of Directors
SANTA CLARA, Calif., Dec. 04, 2019 -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the.
- Thomson Reuters StreetEvents
Edited Transcript of NERV earnings conference call or presentation 4-Nov-19 1:30pm GMT
Q3 2019 Minerva Neurosciences Inc Earnings Call
- GlobeNewswire
Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 21, 2019
WALTHAM, Mass., Nov. 14, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to.
- Insider Monkey
Minerva Neurosciences, Inc (NERV): Are Hedge Funds Right About This Stock?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- GlobeNewswire
Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates
WALTHAM, Mass., Nov. 04, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central.
- GlobeNewswire
Minerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019
WALTHAM, Mass., Oct. 28, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central.
- Simply Wall St.
Does The Minerva Neurosciences, Inc. (NASDAQ:NERV) Share Price Tend To Follow The Market?
Anyone researching Minerva Neurosciences, Inc. (NASDAQ:NERV) might want to consider the historical volatility of the...
- PR Newswire
Investor Alert: Kaplan Fox Investigates Minerva Neurosciences, Inc. (NASDAQ: NERV)
NEW YORK , Oct. 1, 2019 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) has been investigating claims on behalf of investors who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: ...
- Investing.com
Stocks - U.S. Steel Slumps, Spotify, Tesla Rise Premarket
Investing.com - Stocks in focus in premarket trading on Tuesday:
- MarketWatch
Minerva's stock plunges to lead all premarket losers after cyber-attack delays enrollment in a phase 3 trial
Shares of Minerva Neurosciences Inc. plummeted 28% to pace all premarket decliners Tuesday, after the biopharmaceutical company said a cyber-attack on an external contractor resulted in delays in patient recruitment for the phase 3 trial of its schizophrenia treatment, roluperidone. The company said a total of 384 patients of a targeted 501 have been enrolled, with complete enrollment now expected at year end, and top-line results expected in the first half of 2020. Separately, the company said patient screening for a phase 2b trial of its major depressive disorder treatment, MIN-117, has been completed, with top-line results expected in the fourth quarter of 2019; and a study of its MDD treatment seltorexant showed a "quantitative advantage" over quetiapine. Minerva's stock has gained 15.0% year to date through Monday, while the iShares Nasdaq Biotechnology ETF has tacked on 3.2% and the S&P 500 has advanced 18.7%.
- GlobeNewswire
Minerva Neurosciences Announces Update for Three Clinical Trials
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced an update on three clinical-stage programs with roluperidone (MIN-101), seltorexant (MIN-202) and MIN-117. The Company will hold a conference call at 8:30 a.m. today to discuss these programs (see dial-in information below). Due to a cyber-attack on one of the Company’s external contractors that resulted in a disruption to patient recruitment in the study, the Company now expects to complete enrollment at approximately year-end and anticipates top-line results from the 12-week, double-blind portion of the study to be available in the first half of 2020. MIN-117: Patient screening has been completed in the Phase 2b trial of MIN-117 in moderate to severe major depressive disorder (MDD). Top-line results are expected in the fourth quarter of 2019.
- GlobeNewswire
Minerva Neurosciences to Host Conference Call and Live Webcast on Tuesday, October 1 at 8:30 AM ET
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, will hold a conference call and live audio webcast on October 1, 2019, at 8:30 a.m. Eastern Time to provide updates on the roluperidone Phase 3 clinical trial in schizophrenia, the seltorexant 2002 clinical trial in major depressive disorder (MDD) and the MIN-117 clinical trial in MDD.
- GlobeNewswire
Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone
WALTHAM, Mass. and SOMERSET, N.Y., Sept. 24, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of.
- Zacks
Zacks.com featured highlights include: ACM Research, GAIN Capital, Cutera, Columbus McKinnon and Minerva
Zacks.com featured highlights include: ACM Research, GAIN Capital, Cutera, Columbus McKinnon and Minerva
- Zacks
Moving Average Crossover Alert: Minerva Neurosciences
Minerva Neurosciences is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- Zacks
5 Stocks to Buy on New Analyst Coverage
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
- Simply Wall St.
What Kind Of Shareholder Appears On The Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Shareholder Register?
Every investor in Minerva Neurosciences, Inc. (NASDAQ:NERV) should be aware of the most powerful shareholder groups...
- Thomson Reuters StreetEvents
Edited Transcript of NERV earnings conference call or presentation 5-Aug-19 12:30pm GMT
Q2 2019 Minerva Neurosciences Inc Earnings Call
Motley FoolMinerva Neurosciences, Inc. (NERV) Q2 2019 Earnings Call Transcript
NERV earnings call for the period ending June 30, 2019.
- GlobeNewswire
Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates
During the Second Quarter, Minerva announced several important clinical advancements, including positive top line results from two Phase 2b studies of seltorexant (MIN-202) in.
- GlobeNewswire
Minerva Neurosciences to Report Second Quarter 2019 Financial Results and Business Updates on August 5, 2019
WALTHAM, Mass., July 29, 2019 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central.
- Simply Wall St.
Did Minerva Neurosciences, Inc. (NASDAQ:NERV) Insiders Buy Up More Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
- Insider Monkey
Is Minerva Neurosciences, Inc (NERV) A Good Stock To Buy?
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]
- Benzinga
Minerva Spikes Higher After Novel Insomnia Drug Aces Mid-Stage Trial
Shares of thinly traded micro-cap biotech Minerva Neurosciences Inc (NASDAQ: NERV ) spiked higher on Monday. What Happened Minerva announced results of a Phase 2b study that evaluated its seltorexant, ...
